GLAND.NS Profit & Loss
Gland Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:36
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹36.25 Bn | ₹56.65 Bn | ₹56.17 Bn | ₹64.31 Bn | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹2.40 Bn | ₹1.70 Bn | ₹2.14 Bn | ₹3.16 Bn | OtherIncome |
| Total Income | ₹38.65 Bn | ₹58.35 Bn | ₹58.30 Bn | ₹67.47 Bn | Income |
| Cost of Materials Consumed | ₹17.17 Bn | ₹20.22 Bn | ₹19.72 Bn | ₹22.40 Bn | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹0.16 Bn | ₹0.23 Bn | ₹0.14 Bn | ₹0.07 Bn | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-0.47 Bn | ₹1.28 Bn | ₹1.03 Bn | ₹-0.03 Bn | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹4.03 Bn | ₹12.57 Bn | ₹14.02 Bn | ₹16.29 Bn | EmployeeBenefitExpense |
| Finance Costs | ₹0.07 Bn | ₹0.26 Bn | ₹0.42 Bn | ₹0.33 Bn | FinanceCosts |
| Depreciation and Amortisation | ₹1.47 Bn | ₹3.45 Bn | ₹3.78 Bn | ₹4.24 Bn | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹5.11 Bn | ₹9.02 Bn | ₹8.56 Bn | ₹9.29 Bn | OtherExpenses |
| Total Expenses | ₹27.54 Bn | ₹47.02 Bn | ₹47.67 Bn | ₹52.58 Bn | Expenses |
| Profit Before Exceptional Items and Tax | ₹11.11 Bn | ₹11.33 Bn | ₹10.63 Bn | ₹14.89 Bn | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹-0.56 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹-0.24 Bn | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹10.55 Bn | ₹11.33 Bn | ₹10.63 Bn | ₹14.65 Bn | ProfitBeforeTax |
| Tax Expense | ₹2.74 Bn | ₹3.60 Bn | ₹3.64 Bn | ₹4.37 Bn | TaxExpense |
| Net Profit (incl. minority interest) | ₹7.81 Bn | ₹7.72 Bn | ₹6.99 Bn | ₹10.27 Bn | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹7.81 Bn | ₹7.72 Bn | ₹6.99 Bn | ₹10.27 Bn | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹47.44 | ₹46.90 | ₹42.40 | ₹62.35 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹47.43 | ₹46.89 | ₹42.40 | ₹62.28 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from GLAND.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).